作用靶点：PPI

参考靶点：Potassium-transporting ATPase alpha chain 1; Microtubule-associated protein tau

作用机制：Lansoprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but rather suppress gastric acid secretion by specific inhibition of the (H+,K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the parietal cell, Lansoprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose-related and leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus.

六、中国临床试验数据库（29条）

• 心衰治疗里程碑突破！首个miRNA药物证明安全有效！
• RNA 靶向药物｜设计策略与生产工艺优化
• 中山大学吴钧团队AFM：古老药物的重生！无药载体也能抗癌
• 乙肝药物靶标设计方向，核心蛋白HBc，在HBV复制中起重要作用
• Nature 综述导读：FDA 批准第 100 个抗体药物！抗体药物的研究方向在哪里？
• 抗抑郁药物与妊娠
• CGRP靶向偏头痛药物头对头研究！礼来启动Emgality四期临床试验
• 又一阿尔茨海默病药物获批！半年内已有四款盐酸美金刚口服药获批
• 初步探索：为什么「他汀类药物」会增加糖尿病风险？
• 疾病预防|前列腺癌，早期进展缓慢，发现可治愈，最有效的是这5种药物